Synthesis,
DCL ligand
iodine radioisotopes
prostate cancer
prostate-specific membrane antigen
radiolabeled pharmaceuticals
targeted delivery
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
30 Jul 2023
30 Jul 2023
Historique:
received:
30
06
2023
revised:
24
07
2023
accepted:
24
07
2023
medline:
14
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
Prostate-specific membrane antigen (PSMA) has been identified as a target for the development of theranostic agents. In our current work, we describe the design and synthesis of novel N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-(S)-L-lysine (DCL) urea-based PSMA inhibitors with a chlorine-substituted aromatic fragment at the lysine ε-nitrogen atom, a dipeptide including two phenylalanine residues in the L-configuration as the peptide fragment of the linker, and 3- or 4-(tributylstannyl)benzoic acid as a prosthetic group in their structures for radiolabeling. The standard compounds [
Identifiants
pubmed: 37569582
pii: ijms241512206
doi: 10.3390/ijms241512206
pmc: PMC10418939
pii:
doi:
Substances chimiques
Iodine-123
8YWR746RPQ
Iodine Radioisotopes
0
Urea
8W8T17847W
Glutamate Carboxypeptidase II
EC 3.4.17.21
Antigens, Surface
0
Radiopharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : TPU development program Priority 2030
ID : Priority-2030-NIP/IS-042-375-2023
Organisme : Russian Science Foundation
ID : 22-15-00098, https://rscf.ru/project/22-15-00098/ (Synthesis of PSMA ligands)
Organisme : Russian Science Foundation
ID : No: 21-13-00023
Organisme : President of the Russian Federation
ID : MK-3748.2022.1.3
Références
EJNMMI Res. 2015 Dec;5(1):68
pubmed: 26608882
J Med Chem. 2016 Mar 10;59(5):1761-75
pubmed: 26878194
Molecules. 2020 Dec 08;25(24):
pubmed: 33302417
Bioorg Med Chem Lett. 2022 Sep 1;71:128840
pubmed: 35661685
J Med Chem. 2021 Apr 22;64(8):4532-4552
pubmed: 33822606
Bioconjug Chem. 2019 Jun 19;30(6):1805-1813
pubmed: 31075200
Int J Oncol. 2019 Apr;54(4):1209-1220
pubmed: 30968147
J Pept Sci. 2016 Jan;22(1):4-27
pubmed: 26785684
Nat Protoc. 2006;1(2):707-13
pubmed: 17406300
J Med Chem. 2001 Feb 1;44(3):298-301
pubmed: 11462970
EJNMMI Res. 2012 Jun 06;2(1):23
pubmed: 22673157
Bioconjug Chem. 2007 Jul-Aug;18(4):1226-40
pubmed: 17583925
Bioorg Med Chem Lett. 2019 Aug 15;29(16):2229-2235
pubmed: 31248772
Pharmaceutics. 2019 Aug 02;11(8):
pubmed: 31382362
Cancer J. 2016 Sep/Oct;22(5):347-352
pubmed: 27749329
Prostate. 2019 May;79(6):604-613
pubmed: 30663074
J Med Chem. 2021 Apr 22;64(8):4960-4971
pubmed: 33826320
J Cell Biochem. 2007 Oct 15;102(3):571-9
pubmed: 17685433
J Med Chem. 2003 May 8;46(10):1989-96
pubmed: 12723961
Int J Mol Sci. 2022 Nov 09;23(22):
pubmed: 36430267
Mol Cancer Ther. 2018 Oct;17(10):2176-2186
pubmed: 30065100
J Med Chem. 1996 Jan 19;39(2):619-22
pubmed: 8558536
Pharmaceutics. 2022 May 20;14(5):
pubmed: 35631684
Theranostics. 2015 Oct 18;5(12):1388-401
pubmed: 26681984
J Med Chem. 2021 Dec 9;64(23):17123-17145
pubmed: 34797052
Eur Urol. 2015 Sep;68(3):530-4
pubmed: 25957851
World J Surg. 2006 Apr;30(4):628-36
pubmed: 16555021
Chem Rev. 2009 Jun;109(6):2455-504
pubmed: 19364121
Mol Pharm. 2009 May-Jun;6(3):790-800
pubmed: 19361232
J Nucl Med. 2015 Aug;56(8):1169-76
pubmed: 26089548
J Med Chem. 2010 Nov 11;53(21):7767-77
pubmed: 20936874
Int J Nanomedicine. 2016 Aug 12;11:3939-50
pubmed: 27574424
J Med Chem. 2009 Jan 22;52(2):347-57
pubmed: 19111054
J Drug Target. 2016 Sep;24(8):679-93
pubmed: 26887438
Mol Pharm. 2018 Aug 6;15(8):3502-3511
pubmed: 29920108
Cancer Res. 2009 Sep 1;69(17):6932-40
pubmed: 19706750